[
  {
    "ts": null,
    "headline": "Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of […]",
    "url": "https://finnhub.io/api/news?id=14ec0f8cb2231444090d6225bcbf24a2096e414cc6707a93cb31e81e5924baef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749980330,
      "headline": "Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025",
      "id": 135284084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of […]",
      "url": "https://finnhub.io/api/news?id=14ec0f8cb2231444090d6225bcbf24a2096e414cc6707a93cb31e81e5924baef"
    }
  }
]